Glepaglutide Improves Short Bowel Syndrome Patients’ Ability to Get Nutrients from Food, Trial Shows

Glepaglutide Improves Short Bowel Syndrome Patients’ Ability to Get Nutrients from Food, Trial Shows
Zealand Pharma's glepaglutide (ZP1848) improves short bowel syndrome patients' ability to absorb nutrients from food, according to a Phase 2 clinical trial.
The condition, also known as SBS, occurs when part of the small intestine is missing. Its hallmark is patients being unable to absorb enough nutrients into their body.
It usually results from surgery to deal with Crohn's disease, ischemia or radiation damage. Ischemia is an insufficient supply of blood to an organ, usually because of a blocked artery.
SBS is a life-threatening chronic disease. Those with severe cases can become dependent on dail
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *